Taken together, these findings suggest that inhibition of HDAC1,2 activity impinges on the viability and cell cycle progression of refractory DLBCL cells likely by affecting processes other than EZH2 regulated gene expression. The gene discussed is HDAC1; the disease is diffuse large B-cell lymphoma.